Lenacapavir Approval: What to Know When Selecting a PrEP Regimen
Tune in to learn how the recent FDA approval of lenacapavir (LEN) for PreP integrates into the current field of HIV prevention. Listen on the go or follow along with our expert-curated slides.
Decera Clinical Education Infectious Disease Podcast · Colleen F. Kelley MD MPH, Raphael J. Landovitz MD MSc
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Tune in to learn how the recent FDA approval of lenacapavir (LEN) for PreP integrates into the current field of HIV prevention. Listen on the go or follow along with our expert-curated slides. Topics covered include:
- The current landscape of PrEP
- FDA approval of lenacapavir
- Phase III efficacy and safety data for lenacapavir
- Recommendations and perspectives on the future of PrEP
Presenters:
Colleen F. Kelley, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Co-Director, Emory Center for
AIDS Research
Associated Dean for Research,
Emory at Grady
Emory University School of Medicine
Atlanta, Georgia
Raphael J. Landovitz, MD, MSc
Professor of Medicine
Chief, Division of Infectious Diseases
Associate Vice Chair for
Clinical Research
Department of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Research & Education (CARE)
Director, Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Los Angeles, California
Link to full program:
https://bit.ly/4m8RaOg
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.